[CAS NO. 142001-63-6] Saredutant

Name: Saredutant
Brand: Arctom Scientific
SKU: HY-106910

Ships within Stock Price Qty Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [142001-63-6]

Fulfillment

Catalog

HY-106910

Brand

MCE

CAS

142001-63-6

DESCRIPTION [142001-63-6]

Overview

MDL	-
Molecular Weight	552.53
Molecular Formula	C31H35Cl2N3O2
SMILES	CC(NC1(C2=CC=CC=C2)CCN(CC[C@@H](C3=CC(Cl)=C(Cl)C=C3)CN(C)C(C4=CC=CC=C4)=O)CC1)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Respir Physiol Neurobiol. 2022 Jul 26;103952.

Summary

Saredutant is a selective NK2 receptor antagonist.

IC50 & Target

NK2

In Vivo

Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Saredutant has dose-dependent effects on swim test immobility, with the low dose of 1 mg/kg having no effect and the doses of 3 and 10 mg/kg significantly reducing immobility ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00531622	Sanofi	Major Depressive Disorder	September 2007	Phase 3
NCT00429260	Sanofi	Depressive Disorder	January 2007	Phase 3
NCT00250601	Sanofi	Depressive Disorder	April 2005	Phase 3
NCT00256113	Sanofi	Depressive Disorder	December 2004	Phase 3
NCT00250614	Sanofi	Depressive Disorder	April 2005	Phase 3
NCT00336713	Sanofi	Depressive Disorder	May 2006	Phase 3
NCT00250627	Sanofi	Depressive Disorder	December 2004	Phase 3
NCT00390650	Sanofi	Anxiety	October 2006	Phase 3
NCT00629551	Sanofi	Depressive Disorder, Major	February 2008	Phase 3
NCT00417118	Sanofi	Generalized Anxiety	December 2006	Phase 3
NCT00390533	Sanofi	Generalized Anxiety	September 2006	Phase 3
NCT00250653	Sanofi	Depressive Disorder	May 2005	Phase 3
NCT00415142	Sanofi	Depressive Disorder	December 2006	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 452.46 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8099 mL	9.0493 mL	18.0986 mL
5 mM	0.3620 mL	1.8099 mL	3.6197 mL
10 mM	0.1810 mL	0.9049 mL	1.8099 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (3.76 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (3.76 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.76 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Overstreet DH, et al. Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with Desipramine in an animal model of depression. Pharmacol Biochem Behav. 2010 Aug;96(2):206-10.

Synonyms

Benzamide, N-[(2S)-4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-

Benzamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, (S)-

N-[(2S)-4-[4-(Acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide

SR 48968

Saredutant

SR 48968C